A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer



Status:Terminated
Conditions:Colorectal Cancer, Cancer, Other Indications
Therapuetic Areas:Oncology, Other
Healthy:No
Age Range:18 - Any
Updated:8/25/2017
Start Date:March 2013
End Date:June 2017

Use our guide to learn which trials are right for you!

Phase III Double-blinded, Placebo Controlled Study of Xilonix™ for Improving Survival in Metastatic Colorectal Cancer

The purpose of this study is to determine if the True Human Monoclonal antibody Xilonix
(MABp1) can prolong the life of colorectal carcinoma patients that are refractory to standard
therapy.

In the setting of refractory, metastatic disease a complete resolution of tumor burden is not
a reasonable expectation. Instead, the primary goal of anti-tumor therapy at this stage is to
eliminate or reduce the symptomatic effects of the tumor, while trying to prolong survival
for as long as possible. Due to treatment related morbidity however, few treatment modalities
are ideal for this objective. Even with the most recent targeted agents (such as multi-kinase
inhibitors), drug related toxicities frequently lead to relatively short treatment durations.
With discontinuation of therapy, disease progression is uncontrolled and prognosis is poor.

New agents that control disease progression—while improving tumor-related symptoms, rather
than causing significant therapy related morbidity—are vitally needed to treat patients with
advanced cancer, including those with colorectal cancer. An approach has been taken to
develop such an agent using a monoclonal antibody to block the chronic inflammation involved
in both malignant disease progression and constitutional symptoms.

Xilonix™ is expected to inhibit tumor growth and metastasis by interrupting crucial signals
that drive angiogenesis and invasiveness. The antibody therapy may also block tumor
microenvironment infiltration by leukocytes (such as myeloid suppressor cells) that suppress
antitumor immunity, enabling better host immune control of the disease. In addition to local
effects on the tumor, Xilonix™ is expected to work systemically to correct the metabolic
dysregulation, fatigue and anxiety mediated by chronic inflammatory signaling to the central
nervous system.

Inclusion Criteria:

1. Subjects with pathologically confirmed colorectal carcinoma that is metastatic or
unresectable and which is refractory to standard therapy. To be considered refractory,
a subject must have experienced progression (or intolerance) after treatment with
standard approved regimens including, oxaliplatin, irinotecan flouropyrimidine,
bevacizumab, and cetuximab or panitumumab if KRAS wildtype.

2. Subjects will not be treated with any radiation, chemotherapy, or investigational
agents while enrolled in this protocol.

3. Eastern Cooperative Oncology Group (ECOG) performance status 0,1, or 2.

4. At least 2 weeks since the last previous cancer treatment including: chemotherapy,
radiation therapy, immunotherapy, surgery, hormonal therapy, or targeted biologics.

5. Age ≥ 18 years, male or female subjects.

6. Serum potassium and magnesium levels within institutional normal limits. Total serum
calcium or ionized calcium level must be greater than or equal to the lower limit of
normal.

7. Adequate renal function, defined by serum creatinine ≤ 1.5 x ULN.

8. Adequate hepatic function

9. Adequate bone marrow function

10. For women of childbearing potential (WOCBP), a negative serum pregnancy test result at
Screening.

11. Signed and dated institutional review board (IRB)-approved informed consent before any
protocol-specific screening procedures are performed.

12. Patients enrolled must, in the Investigator's judgment, be healthy enough to stay on
the clinical trial for three months.

Exclusion Criteria:

1. Mechanical obstruction that would prevent adequate oral nutritional intake.

2. Serious uncontrolled medical disorder, or active infection, that would impair the
ability of the patient to receive protocol therapy.

3. Uncontrolled or significant cardiovascular disease, including:

4. Dementia or altered mental status that would prohibit the understanding or rendering
of informed consent.

5. Subjects who have not recovered from the adverse effects of prior therapy at the time
of enrollment to ≤ grade 1; excluding alopecia and grade 2 neuropathy.

6. Immunocompromised subjects, including subjects known to be infected with human
immunodeficiency virus (HIV).

7. Known hepatitis B surface antigen and/or positive hepatitis C antibody and presence of
hepatitis C RNA.

8. History of tuberculosis (latent or active) or positive Interferon-gamma release assay
(IGRA).

9. Receipt of a live (attenuated) vaccine within 1 month prior to Screening

10. Subjects with history of hypersensitivity to compounds of similar chemical or biologic
composition of XILONIX™.

11. Women who are pregnant or breastfeeding.

12. WOCBP or men whose sexual partners are WOCBP who are unwilling or unable to use an
acceptable method of contraception for at least 1 month prior to study entry, for the
duration of the study, and for at least 3 months after the last dose of study
medication.

13. Weight loss >20% in the previous 6 months.
We found this trial at
31
sites
Miami, Florida
Principal Investigator: Antonio Ucar, MD
Phone: 281-863-6544
?
mi
from
Miami, FL
Click here to add this to my saved trials
8700 Beverly Blvd # 8211
Los Angeles, California 90048
(1-800-233-2771)
Cedars Sinai Med Ctr Cedars-Sinai is known for providing the highest quality patient care. Our...
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Albuquerque, New Mexico 87109
Principal Investigator: Fa-Chyi Lee, MD
?
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Bedford and Grapevine, Texas 76022
Principal Investigator: Thomas Anderson, MD
Phone: 281-863-6544
?
mi
from
Bedford and Grapevine, TX
Click here to add this to my saved trials
Chattanooga, Tennessee 37404
Principal Investigator: Mark Womack, MD
Phone: 423-698-1844
?
mi
from
Chattanooga, TN
Click here to add this to my saved trials
5053 Wooster Rd
Cincinnati, Ohio 45226
(513) 751-2273
Principal Investigator: Irfan Firdaus, DO
Phone: 513-751-2273
Oncology Hematology Care Our more than 60 physicians and advanced practice providers throughout neighborhood offices...
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Dallas, Texas
Principal Investigator: Kristi McIntyre, MD
Phone: 281-863-6544
?
mi
from
Dallas, TX
Click here to add this to my saved trials
Detroit, Michigan 48201
Principal Investigator: Minsig Choi, MD
Phone: 313-576-9385
?
mi
from
Detroit, MI
Click here to add this to my saved trials
800 West Magnolia Avenue
Fort Worth, Texas 76104
?
mi
from
Fort Worth, TX
Click here to add this to my saved trials
1001 12th Avenue
Fort Worth, Texas 76104
?
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Fullerton, California 92835
Principal Investigator: David Park, MD
Phone: 714-446-5642
?
mi
from
Fullerton, CA
Click here to add this to my saved trials
La Jolla, California 92093
Principal Investigator: Eric Roeland, MD
Phone: 858-534-5532
?
mi
from
La Jolla, CA
Click here to add this to my saved trials
Longview and Tyler, Texas
Principal Investigator: Donald Richards, MD
Phone: 281-863-6544
?
mi
from
Longview and Tyler, TX
Click here to add this to my saved trials
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
2312 North Nevada Avenue
Multiple Locations, Colorado 80907
?
mi
from
Multiple Locations, CO
Click here to add this to my saved trials
1950 Glenn Mitchell Drive
Multiple Locations, Virginia 23456
?
mi
from
Multiple Locations, VA
Click here to add this to my saved trials
Nashville, Tennessee
Principal Investigator: Johannna Bendell, MD
Phone: 615-329-7235
?
mi
from
Nashville, TN
Click here to add this to my saved trials
New Braunfels and San Antonio, Texas
Principal Investigator: Alexander Zweibach, MD
Phone: 281-863-6544
?
mi
from
New Braunfels and San Antonio, TX
Click here to add this to my saved trials
New York, New York 10021
Principal Investigator: Tong Dai, MD
Phone: 646-962-9353
?
mi
from
New York, NY
Click here to add this to my saved trials
Palo Alto, California 94304
Principal Investigator: George Fisher, MD
Phone: 650-724-2056
?
mi
from
Palo Alto, CA
Click here to add this to my saved trials
Philadelphia, Pennsylvania 19141
Principal Investigator: John Leighton, MD
Phone: 215-456-8295
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Portland and Yualatin, Oregon
Principal Investigator: Spencer Shao, MD
Phone: 281-863-6544
?
mi
from
Portland and Yualatin, OR
Click here to add this to my saved trials
San Antonio, Texas 78234
Principal Investigator: Alexander Brown, MD
Phone: 210-916-3332
?
mi
from
San Antonio, TX
Click here to add this to my saved trials
St Leonards, New South Wales 2065
?
mi
from
St Leonards,
Click here to add this to my saved trials
Temple, Texas 76508
Principal Investigator: Lucas Wong, MD
Phone: 254-724-5939
?
mi
from
Temple, TX
Click here to add this to my saved trials
The Bronx, New York 10467
?
mi
from
The Bronx, NY
Click here to add this to my saved trials
Thomasville, Georgia 31792
Principal Investigator: Teresa Coleman, MD,FACP
Phone: 229-584-5468
?
mi
from
Thomasville, GA
Click here to add this to my saved trials
Tucson, Arizona 85745
Principal Investigator: Christopher DiSimone, MD
Phone: 281-863-6544
?
mi
from
Tucson, AZ
Click here to add this to my saved trials
Tyler, Texas
Principal Investigator: Hitesh Singh, MD
Phone: 903-877-5831
?
mi
from
Tyler, TX
Click here to add this to my saved trials
Vancouver, Washington 98686
?
mi
from
Vancouver, WA
Click here to add this to my saved trials
Whittier, California 90603
Principal Investigator: Christopher Ho, MD
Phone: 562-693-4477
?
mi
from
Whittier, CA
Click here to add this to my saved trials